

Edited by
Abel Lajtha

Handbook of
Neurochemistry
SECOND EDITION

10

**PATHOLOGICAL
NEUROCHEMISTRY**

Handbook of ***Neurochemistry***

SECOND EDITION

Volume 10
**PATHOLOGICAL
NEUROCHEMISTRY**

Edited by

Abel Lajtha

*Center for Neurochemistry
Wards Island, New York*



PLENUM PRESS • NEW YORK AND LONDON

Library of Congress Cataloging in Publication Data

Main entry under title:

Handbook of neurochemistry.

Includes bibliographies and indexes.

Contents: v. 1. Chemical and cellular architecture—[etc.]—v. 7. Structural elements of the nervous system— —v. 10. Pathological neurochemistry.

1. Neurochemistry—Handbooks, manuals, etc. I. Lajtha, Abel. [DNLM: 1. Neurochemistry. WL 104 H434]

QP356.3.H36 1982

612'.814

82-493

ISBN 0-306-41744-8 (v. 10)

©1985 Plenum Press, New York
A Division of Plenum Publishing Corporation
233 Spring Street, New York, N.Y. 10013

All rights reserved

No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise, without written permission from the Publisher

Printed in the United States of America

Contributors

Naren L. Banik, Department of Neurology, Medical University of South Carolina, Charleston, South Carolina 29425

Norman H. Bass, Department of Neurology, Lexington Veterans Administration Medical Center and University of Kentucky College of Medicine, and Sanders Brown Research Center on Aging, Lexington, Kentucky 40536

L. Battistin, Clinica delle Malattie Nervose e Mentali, Università di Padova, 35100 Padova, Italy

Charles J. Billington, Division of Endocrinology, Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455

Samuel Bogoch, Department of Biochemistry, Foundation for Research on the Nervous System and Boston University School of Medicine, Boston, Massachusetts 02215

S. Winston Bogoch, College of Physicians and Surgeons, Columbia University, New York, New York 10032

Roscoe O. Brady, Developmental and Metabolic Neurology Branch, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20205

Pak Hoo Chan, Department of Neurology, University of California School of Medicine, San Francisco, California 94143

Jørgen Clausen, The Neurochemical Institute, DK-2200 Copenhagen, Denmark, and the Institute for Biology and Chemistry, Roskilde University, DK-4000 Roskilde, Denmark

M. Dam, Clinica delle Malattie Nervose e Mentali, Università di Padova, 35100 Padova, Italy

Steven T. DeKosky, Department of Neurology, Lexington Veterans Administration Medical Center and University of Kentucky College of Medicine, and Sanders Brown Research Center on Aging, Lexington, Kentucky 40536

Lynn Eleanor DeLisi, Neurogenetics Branch, Intramural Research Program, National Institute of Mental Health, Bethesda, Maryland 20205

Darryl C. De Vivo, Division of Pediatric Neurology, Columbia University College of Physicians and Surgeons, New York, New York 10032

Salvatore DiMauro, Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York 10032

Pierre M. Dreyfus, Department of Neurology, University of California School of Medicine, Davis, California 95616

Barney E. Dwyer, Epilepsy and Neurology Research Laboratories, Veterans Administration Medical Center, Sepulveda, California 91343; and Department of Neurology and The Brain Research Institute, University of California School of Medicine, Los Angeles, California 90024

K. A. C. Elliot, Department of Biochemistry, McGill University, Montreal, Quebec H3G 1Y6 Canada

Robert A. Fishman, Department of Neurology, University of California School of Medicine, San Francisco, California 94143

E. Geller, Neurobiochemistry Laboratory, Veterans Administration Medical Center, Los Angeles, California 90073; and Department of Psychiatry, University of California, Los Angeles, California 90024

Mark S. Gold, Fair Oaks Hospital and Psychiatric Diagnostic Laboratory of America, Summit, New Jersey 07901

Ashley T. Haase, Departments of Medicine and Microbiology and Immunology, University of California School of Medicine, San Francisco, California 94143; and Veterans Administration Hospital, San Francisco, California 94121

Theodore A. Hare, Department of Pharmacology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107

Henrik A. Hartmann, Department of Pathology, University of Wisconsin Medical School, Madison, Wisconsin 53706

George A. Hashim, The Jane Forbes Clark Surgical Research Laboratories, Departments of Surgery and Microbiology, St. Luke's-Roosevelt Hospital Center and Columbia University, New York, New York 10032

Edith Heilbronn, Unit of Neurochemistry and Neurotoxicology, University of Stockholm, S-172 46 Sundbyberg, Sweden

Edward L. Hogan, Department of Neurology, Medical University of South Carolina, Charleston, South Carolina 29425

- F. A. Hommes*, Department of Cell and Molecular Biology, Medical College of Georgia, Augusta, Georgia 30912
- D. Karcher*, Laboratory of Neurochemistry, Born-Bunge Foundation, Universitaire Instelling Antwerpen, B-2610 Antwerp, Belgium
- Yasuo Kishimoto*, John F. Kennedy Institute and Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205
- A. Lowenthal*, Laboratory of Neurochemistry, Born-Bunge Foundation, Universitaire Instelling Antwerpen, B-2610 Antwerp, Belgium
- Erik Lycke*, Department of Virology, Institute of Medical Microbiology, University of Göteborg, 413 46 Göteborg, Sweden
- Anne M. Morin*, Epilepsy and Neurology Research Laboratories, Veterans Administration Medical Center, Sepulveda, California 91343; and Department of Neurology and The Brain Research Institute, University of California School of Medicine, Los Angeles, California 90024
- John E. Morley*, Neuroendocrine Research Laboratory, Veterans Administration Medical Center, Minneapolis, Minnesota 55417
- Hugo W. Moser*, John F. Kennedy Institute, Baltimore, Maryland 21205
- F. Petty*, Veterans Administration Medical Center and Department of Psychiatry, University of Texas, Dallas, Texas 75216
- Stanley B. Prusiner*, Departments of Neurology and Biochemistry and Biophysics, University of California, San Francisco, California 94143
- E. Ritvo*, Department of Psychiatry, University of California, Los Angeles, California 90024
- Susan Y. Schmidt*, Berman-Gund Laboratory for the Study of Retinal Degenerations, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts 02114
- A. D. Sherman*, Department of Psychiatry, University of Iowa College of Medicine, Iowa City, Iowa 52242
- Kunihiko Suzuki*, Rose F. Kennedy Center and Department of Neurology, Albert Einstein College of Medicine, Bronx, New York 10461
- Ara Tourian*, Neurogenetics and Cell Biology Laboratory, Department of Medicine, Division of Neurology, Duke University Medical Center, Durham, North Carolina 27710
- Karl Verebey*, New York State Division of Substance Abuse Services Testing and Research Laboratory; and Department of Psychiatry, Downstate Medical School, Brooklyn, New York 11217

Claude G. Wasterlain, Epilepsy and Neurology Research Laboratories, Veterans Administration Medical Center, Sepulveda, California 91343; and Department of Neurology and The Brain Research Institute, University of California School of Medicine, Los Angeles, California 90024

G. Winokur, Department of Psychiatry, University of Iowa College of Medicine, Iowa City, Iowa 52242

James H. Wood, Cerebral Blood Flow Laboratories, Division of Neurosurgery, Emory University Clinic, Atlanta, Georgia 30322

Richard Jed Wyatt, Neuropsychiatry Branch, Intramural Research Program, National Institute of Mental Health, Saint Elizabeths Hospital, Washington, D.C. 20032

M. B. H. Youdim, Rappaport Family Institute for Research in the Medical Sciences, Department of Pharmacology, Technion, Haifa, Israel

A. Yuwiler, Neurobiochemistry Laboratory, Veterans Administration Medical Center, Los Angeles, California 90073; and Department of Psychiatry, University of California, Los Angeles, California 90024

Preface

More than for any other volume of the *Handbook of Neurochemistry*, the chapters in this volume on *Pathological Neurochemistry* deal with the interface of the laboratory bench with the patient's bedside. Most of the chapters reflect the confluence of basic scientists, clinical investigators, and physicians. Considered here are many of the more important disorders that afflict the nerves, muscles, spinal cord, and/or brain of mankind throughout the world. There are well over 500 such disorders. And our understanding of their nature and of measures for effective prevention or treatment depends significantly on application of the biochemical disciplines that characterize neurochemistry.

Before World War II, any attempt to compile a volume on pathological neurochemistry would have been largely descriptive and very rudimentary, as such "handbooks" by Hans Winterstein (1929), Irvine Page (1937), and others demonstrate. But thanks to the many major advances in research and technology in the postwar decades, we now stand at the threshold of understanding how to manage many of the major neurological disorders, and we may expect more such delineations in the immediate decades ahead. Neurochemistry, defined broadly, has played a central role in this extraordinary turn of events, progressing from what J. L. W. Thudichum in 1884 called objects of anxious empiricism to his anticipation of the proud exercise of chemical precision. Indeed, over the next decades we may reasonably expect future editions of this *Handbook* to devote progressively greater space to the pathological and less to the physiological aspects of neurochemistry.

In the present volume, there are notable examples of successful or promising interfaces between the laboratory bench and the clinical bedside. One major advance has been among the genetically determined disorders of the nervous system—in the groups of lipid and mucopolysaccharide storage diseases. The recognition that these disorders arise as consequences of deletions or attenuations of specific lysosomal hydrolases has made possible the development of relatively simple diagnostic and screening procedures and effective prenatal counseling, so that what were once baffling and hopelessly fatal conditions are now susceptible to clinical management and many may soon prove to be treatable by enzyme replacement or analogous therapies.

Major advances have also taken place in the field of movement disorders. The discovery of the neurochemical lesion in Parkinson's disease—the failure of dopamine transmission in nigral neurons—led to the introduction of therapy

with L-DOPA and congeners and the rescue of a sizable adult population group from progressive disability and isolation. In a different way, the even larger problem of epilepsy has been significantly diminished: first, by the devising of practical clinical methods for measuring the circulating levels of anticonvulsant drugs to enhance greatly the clinical management of seizure patients; and second, by the application of the positron-emission tomographic (PET) technique with ^{18}F -labeled 2-deoxyglucose to evaluation of seizure patients *in vivo*. The latter studies have uncovered significant differences between ictal and interictal periods and between seizure foci and adjacent normal brain areas that could not have been anticipated or indeed studied in any other way. The observations of a relatively depressed glucose uptake in areas of seizure foci suggest new research directions for one of the most complex of neurological disorders, epilepsy.

The isolation and purification of receptors for acetylcholine and the exploitation of immunochemical techniques have now provided us with a solution to the problem of myasthenia gravis and with a more rational therapy. Myasthenia gravis may now be clearly classified as an autoimmune disorder. Other potential candidates such as multiple sclerosis seem likely to follow. Surely, the resort to immunochemical techniques carries much promise for many basic and clinical problems of the nervous system. Yet there are challenges as well in such examples as the neurotropic and slow and latent viruses. Not only do viruses or viral particles conceal themselves in neural cells (e.g., the herpes-viruses), but others, like the viruses of poliomyelitis and rabies, may elude general bodily defenses by entering axonal terminals and utilizing axonal transport systems to invade and destroy nerve cells. These are special but important facets of the relevance of newer knowledge about axonal transport to clinical problems. And the analogies provided by such neurotropic viruses seem to point to one of the major trophic mechanisms responsible for the maintenance of connective integrity between pre- and postsynaptic elements.

Another most fruitful area of research concerns the neuropeptides. Here, almost from the beginning, the interface between basic and clinical was clearly perceived. On the one hand, the opiate receptors, enkephalins, drug addiction, and pain mechanisms provided an obvious example that continues to intrigue us with its expanding complexities. We ought not to overlook the fact that pain (its mechanisms and their management) represents one of the most prevalent and important clinical and public health problems facing the world today. On the other hand, there are such examples as the hypothalamic-pituitary systems in which a neurotransmitter such as dopamine regulates the elaboration of certain hypothalamic peptide releasing factors, which in turn control the release of specific pituitary hormones. Moreover such hormones are now known to exhibit significant feedback and other modulatory effects on the central nervous system itself. Thus, the triad of neurotransmitter, neuromodulator, and neurohormone in tandem or even in combination (in one molecule) begins to provide the neurochemical perspective with which to comprehend neuroendocrine, behavioral, and other complex phenomena of central processing.

In fact, the whole problem of central processing still poses many fundamental challenges. Sensory input from specialized receptors for touch, position

sense, pain, light, sound, and the like must be transduced by mechano-, chemo-, photo-, and other specialized receptors into encoded nerve signals that can be centrally analyzed, stored in and recalled from memory, and responded to appropriately. Much more research must be accomplished before we can adequately contend with such disorders of central processing as autism, learning and language disabilities, deafness, blindness, and perhaps even the dementias of the Alzheimer type.

One final area deserves particular attention because of its socioeconomic importance and our as yet rudimentary understanding of the nature of such disorders. Included are cerebrovascular disorders or strokes (the third leading cause of death, after heart disease and cancer, in the United States) and trauma to the central nervous system, primarily head and spinal cord injuries (which afflict the young adult male in particular and are major factors in nearly three-fourths of the fatal accidents in the United States). In fact, these are universal, worldwide problems of a magnitude comparable to that for the United States. For the clinician, and for the neurochemist as well, much of the problem concerns the consequences of these insults to the central nervous system: edema and coma in particular are persisting challenges in terms of mechanisms and of clinical management.

With respect to stroke, recent promising research approaches include the role of prostaglandins in aggregation of platelets, in the control of the caliber of blood vessels, and in the effects of acetylsalicylic acid to inhibit the initial cyclooxygenase step of prostaglandin synthesis from arachidonic acid—all focused on the puzzling problem of pathological mechanisms and prophylaxis in cerebral ischemia and thrombosis. Additionally, more knowledge is needed concerning unique neurochemical aspects of cerebral vessels, which are embryologically and pharmacologically distinct from blood vessels elsewhere in the body.

With respect to central nervous system trauma, a major unsolved problem is why the brain and spinal cord fail to repair damaged areas to achieve spontaneous restoration of function. The tragedy of the wheelchair-bound paraplegic paralyzed below the level of spinal cord injury and unable to regenerate functional connections across the injury gap is the dramatic example. But there are comparable situations for patients with head injury, stroke, multiple sclerosis, and the like. In all cases, the original developmental potential of central axonal outgrowth and establishment of appropriate functional connections among central neurons does not operate when mature brain or spinal cord tissue is damaged. Yet peripheral nerves do regenerate under like circumstances, central connections in nonmammalian species regrow, and in mammals the potential in the central machinery remains. Thus, the neurochemical events and factors involved in developmental and regenerative processes in the mammalian and especially the human central nervous system pose an unusually urgent challenge. In such types of research investigators at the laboratory bench may be involved without realizing the clinical implications and needs.

It seems appropriate to conclude this Preface with a brief review of the dimensions of such clinical problems in the United States today (data for other

countries would be quite comparable). Developmental disorders of the nervous system affect one out of every ten children; there are some one-half million new strokes each year, with 2.5 million Americans continuing to be disabled by stroke; 2 million are legally deaf (and another 12 million have significant hearing impairment); 2 or more million have epilepsy; more than 1.5 million elderly are demented (and account for nearly one-half of all nursing home patients in this country); about 0.5 million have Parkinson's disease; there are 400,000 new cases of head trauma and 10,000 new cases of spinal cord injury each year (with some 100,000 continuing paraplegics); and much more. For example, we have yet to comprehend or to begin to contend with the immense problem of neurotoxicology, especially in the industrial sector. In all, one out of every five persons, or 50 million Americans, are afflicted with neurological or communicative (hearing, speech, language) disorders. The cost to the United States in terms of care, lost income, and the like exceeds 65 billion dollars each year. And the costs to patients in terms of quality of life and to their families in terms of disruptions of home life as well as financial hardship or outright disaster are incalculable. In the case of stroke alone, only 10% of all survivors can return to full activity, whereas fully one-half are so severely disabled that full-time home or institutional care is required.

Yet the expenditures for research by the public and private sectors together amount to considerably less than 400 million dollars annually, or only about 0.5% of the annual cost to society of these disorders. Clearly, a modest increase in the support of research, particularly in the Federal and industrial sectors, would allow us to capitalize on the current upsurge in the neurosciences, as new knowledge and new technologies continue to impinge on us. Two aspects in particular warrant special support and encouragement. One is the training of new investigators (with a special attention to those with clinical orientation) to fill the gaps created by attrition, new fields and technologies, and new academic teaching institutions. The other is the provision of research funding at the interface between the laboratory bench and the patient's bedside. Human research is extraordinarily difficult, demanding, and expensive, and it does not compete well with nonclinical or basic research. Both types are needed, but research on man deserves special attention.

In all of these considerations there is a continuing and vital central role for neurochemistry. Physiological phenomena—electrophysiology, if you will—depend on membrane structure, on ionic gradients and conductance, and on energy metabolism in their support; and on specific transmitters, receptors, and intracellular interactions to generate and display the observed functional phenomena. The same may be said by analogy for pharmacological, immunological, toxicological, endocrinological, and especially behavioral disciplines. In this and preceding volumes in this *Handbook* series, many chapters underscore the central importance of neurochemistry for our understanding of the nervous system, for the management of its disorders, and, indeed, for man himself. For it is his nervous system that makes man human; and it is in its composition, circuitry, awareness of the surrounding world from sensory in-

puts, storage and recall of such experiences, and responses appropriate to its central processing that the human nervous system operates primarily as a chemical entity of marvelous design and superb performance. May careful perusal of this volume bring such understanding and appreciation.

Donald B. Tower

Director-Emeritus, NINCDS, NIH
Asst. Surgeon General (ret), USPHS

Contents

Chapter 1

Disorders of Glycogen Metabolism

Salvatore DiMauro and Darryl C. De Vivo

1. Introduction	1
2. Glycogen Storage Diseases	3
2.1. Glycogenoses Affecting the Brain Directly	4
2.2. Glycogenoses Affecting the Brain Indirectly	9
3. Lafora Disease and Other Polyglucosan Storage Diseases	10
3.1. Myoclonus Epilepsy with Lafora Bodies (Lafora Disease) . . .	10
3.2. Other Polyglucosan Body Disease	11
References	12

Chapter 2

Aminoacidemias and Brain Dysfunction

F. A. Hommes

1. Introduction	15
2. Aminoacidemias	16
2.1. Argininemia	16
2.2. Argininosuccinic Aciduria	17
2.3. Citrullinemia	17
2.4. Histidinemia	18
2.5. Homocystinuria	19
2.6. Hyperammonemia	20
2.7. Hyperlysinemia	20
2.8. Maple Syrup Urine Disease	21
2.9. Nonketotic Hyperglycinemia	22
2.10. Phenylketonuria	26
2.11. Tyrosinemia	34
3. Concluding Comments	34
References	35

Chapter 3

Peptides and Brain Pathology

John E. Morley and Charles J. Billington

1. Methods and Problems of the Investigation of the Role of Peptides in Brain Pathology	43
2. Endogenous Opioid Peptides and Pathology	45
2.1. Opioid Peptides and Analgesia	45
2.2. Hypertension, Diabetes, and Pain	46
2.3. Endogenous Opioid Peptides and Circulatory Pathology	47
2.4. Subacute Necrotizing Encephalomyelopathy and Endogenous Opiates	48
3. Huntington's Disease	48
4. Neuropeptides, Memory, and Aging	49
5. Parkinson's Disease, Multiple Sclerosis, and Spinocerebellar Dysfunction	51
6. Substance P and Shy-Drager Syndrome	51
7. Hypothalamic-Pituitary Syndromes	52
8. Depression and Bipolar Affective Disorders	53
9. Schizophrenia and Neuropeptides	54
10. Neuropeptides and Obesity	56
11. Anorexia Nervosa	57
12. Peptides and the Peripheral Nervous System	58
13. Conclusion	59
References	59

Chapter 4

Neurochemistry of Brain Tumors

Samuel Bogoch and S. Winston Bogoch

1. Introduction	67
2. Membranes and Membrane Receptors	67
3. Nucleic Acids and Polyamines	69
4. Glycolipids and Lipids	70
5. Glycoproteins and Proteins	70
6. Antibodies to Brain Tumors	72
7. Malignin and Related Cancer Recognins	73
References	77

Chapter 5

Lipidoses

Roscoe O. Brady

1. Introduction	81
-----------------------	----

2. Pathological Biochemistry	81
2.1. Gaucher's Disease	81
2.2. Krabbe's Disease	82
2.3. Niemann-Pick Disease	83
2.4. Generalized (G _{M1}) Gangliosidosis	83
3. Genetic Alterations	84
3.1. Proteins That Cross React with Antibodies Raised against Sphingolipid Hydrolases	84
3.2. Activator-Deficiency Diseases	88
3.3. Deficiency of a Stabilizer Glycoprotein in Patients with Combined β -Galactosidase and Neuraminidase Deficiencies..	89
3.4. Significance of Recognizing Types of Genetic Mutations	89
4. Enzyme Replacement Therapy	90
4.1. Replacement of Enzymes in Metabolic Disorders without CNS Involvement	90
4.2. Replacement of Enzymes in Metabolic Disorders with CNS Involvement: Tay-Sachs Disease	92
4.3. Replacement of Enzyme When Both Central and Peripheral Nervous Systems Are Involved: Metachromatic Leukodystrophy	92
5. Strategies for Enzyme Replacement in Metabolic Disorders of the CNS	93
References	94

Chapter 6

Neuropathies with Deranged Metabolism

Hugo W. Moser

1. Classification and Epidemiology of Neuropathies	99
2. Special Tests Available for the Study of Human Peripheral Nerves..	99
2.1. Percutaneous Neurophysiological Techniques	101
2.2. Sural Nerve Biopsy	101
3. Human Neuropathies Associated with Disordered Metabolism	105
3.1. Genetic Neuropathies	105
3.2. Nongenetic Neuropathies	114
4. Concluding Remarks	115
References	115

Chapter 7

RNA in Degenerative Diseases, Aging, and Intoxication

Henrik A. Hartmann

1. Introduction and Methods	119
2. RNA in Motor Neuron Diseases of Man	120

3. RNA in Aging of the Central Nervous System	120
4. RNA in Senile Dementia	121
5. RNA in Mercury Intoxication	121
6. Discussion of Hypotheses	122
References	123

Chapter 8

Adrenoleukodystrophy

Yasuo Kishimoto, Hugo W. Moser, and Kunihiko Suzuki

1. Introduction	125
2. Definition of the Disease	125
3. Identification of Abnormal Very-Long-Chain Fatty Acids in ALD Tissues	126
3.1. Brain	126
3.2. Adrenal Cortex	132
3.3. Peripheral Nerves	133
3.4. Cultured Skin Fibroblasts	133
3.5. Blood	134
3.6. Other Tissues	135
3.7. Summary	135
4. Identification of the Enzyme Defect	137
4.1. Introduction	137
4.2. Metabolism of Cholesterol Esters in ALD	138
4.3. <i>In Vivo</i> Metabolism of Very-Long-Chain Fatty Acids in Cultured Skin Fibroblasts	140
4.4. Defect in Very-Long-Chain Fatty Acid Oxidation in Cultured Skin Fibroblasts from ALD Patients	141
4.5. Localization of the ALD Gene	146
5. Therapeutic Attempts	146
5.1. Nutritional Approach	146
5.2. Attempt to Stimulate Oxidation	147
5.3. Attempt to Remove Very-Long-Chain Fatty Acids	148
6. Pathogenesis of Adrenoleukodystrophy	148
7. Summary	149
References	149

Chapter 9

Brain Edema

Pak Hoo Chan and Robert A. Fishman

1. Introduction	153
2. Definitions and Classifications	153
2.1. Vasogenic Edema	154

2.2. Cellular Edema	154
2.3. Interstitial (Hydrocephalic) Edema	155
3. Measurement of Edema	155
3.1. <i>In Vivo</i> Edema Measurement	155
3.2. <i>In Vitro</i> Edema Measurement	157
4. Biochemistry and Molecular Mechanisms of Brain Edema	158
4.1. Ion Flux and Na ⁺ , K ⁺ -ATPase	158
4.2. Arachidonic Acid and Polyunsaturated Fatty Acids	158
4.3. Oxygen-Derived Free Radicals	161
4.4. Other Edema-Inducing Factors	162
5. Possible Mechanisms for the Development of Brain Edema	163
6. Therapeutic Approaches to Treatment of Brain Edema	165
6.1. Glucocorticoids	166
6.2. Amphiphilic and Membrane-Active Agents	166
6.3. CDP-Choline and CDP-Ethanolamine	167
6.4. Calcium Antagonists	167
6.5. Antioxidants and Free Radical Scavengers	167
6.6. Other Possible Therapeutic Agents	168
References	169

Chapter 10

Multiple Sclerosis

Jørgen Clausen

1. Introduction	175
2. Histological Findings	177
3. Epidemiologic Studies	181
3.1. Topographic Studies	181
3.2. Genetic Implications in Multiple Sclerosis	182
3.3. Epidemiologic Studies on the Virus Antibody Titers in MS ..	184
4. Biochemical and Pathological Findings in Tissue and Biological Fluids	186
4.1. Changes in Nervous Tissue	186
4.2. Changes in the Cerebrospinal Fluid	191
4.3. Changes in Blood	195
5. Treatment of Multiple Sclerosis	197
5.1. Immunologic Intervention	197
5.2. Intervention with the Proteolytic Degradation of Myelin	198
5.3. Dietary Treatment	198
5.4. Neuropharmacological Treatment	199
6. Conclusion	199
References	199